A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Corvallis, Edmond, Fort Collins, Gaithersburg, Hatboro, Hollywood, Lakewood, Las Vegas, Long Beach, Miami, Moore, Myrtle Beach, Norcross, Omaha, Rockville, Springfield, Springville, St Louis, Tampa, Town and Country, and Vestal, United StatesSee the 22 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 698 people enrolled
- Started
- 27 Mar 2023
- Ended
- 20 Nov 2023
- Type of study
- Interventional, 7 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- mRNA-1011.1
- mRNA-1011.2
- mRNA-1012.1
- mRNA-1010
- mRNA-1010.2
- mRNA-1010.3
- Record updated
- 3 February 2025
Who can take part
- Age
- 50 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Body mass index of 18 kilograms (kg)/square meter (m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding
Who cannot take part
- Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1
- Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to the Randomization Visit (for glucocorticosteroids ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed
- Participant has received or plans to receive any licensed or authorized vaccine, including COVID-19 vaccines, ≤28 days prior to the study injection (Day 1) or plans to receive a licensed or authorized vaccine within 28 days after the study injection
- Participant has received a seasonal influenza vaccine or any other influenza vaccine within 180 days prior to the Randomization Visit
- Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to the Randomization Visit
- Participant has had close contact to someone with or been diagnosed themselves with respiratory syncytial virus or SARS-CoV-2 infection as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to the Randomization Visit
- Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Randomization Visit or plans to donate blood products during the study; Note: Other inclusion/exclusion criteria may apply
- Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results
Where in United States
- The Corvallis Clinic, PCCorvallis, United States
- Tekton ResearchEdmond, United States
- Tekton ResearchFort Collins, United States
- CenExel CBHGaithersburg, United States
- Hatboro Medical Associates/CCT ResearchHatboro, United States
- CenExel RCAHollywood, United States
- Critical Care, Pulmonary and Sleep Associates / CCT ResearchLakewood, United States
- Long Beach Research InstituteLakewood, United States
- Healor Primary CareLas Vegas, United States
- Long Beach Clinical TrialsLong Beach, United States
- Suncoast Research Associates, LLCMiami, United States
- Tekton ResearchMoore, United States
- Trial Management Associates, LLCMyrtle Beach, United States
- Georgia Clinic / CCT ResearchNorcross, United States
- Meridian Clinical Research, LLCOmaha, United States
- DelRicht ResearchRockville, United States
- DelRicht ResearchSpringfield, United States
- Springville Dermatology CCT ResearchSpringville, United States
- Sundance Clinical Research, LLCSt Louis, United States
- CenExel FCRTampa, United States
- DelRicht ResearchTown and Country, United States
- Meridian Clinical Research, LLCVestal, United States
About the trial
What the trial wants to find out
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
The 7 groups in the trial
- mRNA-1011.1Treatment being tested
Participants will receive mRNA-1011.1 by intramuscular (IM) injection on Day 1.
- mRNA-1011.2Treatment being tested
Participants will receive mRNA-1011.2 by IM injection on Day 1.
- mRNA-1012.1 Dose Level ATreatment being tested
Participants will receive mRNA-1012.1 at dose level A by IM injection on Day 1.
Treatment: mRNA-1012.1
- mRNA-1012.1 Dose Level BTreatment being tested
Participants will receive mRNA-1012.1 at dose level B by IM injection on Day 1.
Treatment: mRNA-1012.1
- mRNA-1010Existing treatment, for comparison
Participants will receive mRNA-1010 by IM injection on Day 1.
- mRNA-1010.2Existing treatment, for comparison
Participants will receive mRNA-1010.2 by IM injection on Day 1.
- mRNA-1010.3Existing treatment, for comparison
Participants will receive mRNA-1010.3 by IM injection on Day 1.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
- Publications
- Record updated
- 3 February 2025